News Releases

News Releases

Date Title
Sep 3, 2019 Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C.
Aug 26, 2019 Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019
Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 26, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients
Aug 8, 2019 Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Updated 12-month Phase 3 Data will Serve as the Basis for Submission of the BLA On Track for Anticipated Initiation of BLA Submission in 4Q 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics
Aug 5, 2019 Sesen Bio Strengthens Leadership Team
Company Appoints Seasoned Biotech Leaders to Oversee Legal, Corporate Strategy, Financial Planning, and Business Development and Alliance Management CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein
Jul 31, 2019 Sesen Bio to Present at the Canaccord Genuity 39th Annual Growth Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 31, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 39th Annual
Jul 17, 2019 Sesen Bio Announces Retirement of Leslie L. Dan
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 17, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Leslie L. Dan has retired from the Company's Board of Directors, effective
Jun 19, 2019 Sesen Bio Announces Pricing of Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 19, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 20,410,000 shares of its common
Jun 18, 2019 Sesen Bio Announces Proposed Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its
Jun 10, 2019 Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®
FDA Recommends Accelerated Approval Pathway FDA Indicated No Additional Clinical Trials Necessary for BLA Submission Company Expects to Initiate Submission of the BLA in 4Q 2019 Under Rolling Review CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical
Jun 7, 2019 Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Regulatory Update on Pre-BLA Meeting for Vicinium®
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell , President and CEO will host a conference call on  Monday,
Displaying 1 - 10 of 16
Top